OBJECTIVES: To establish the incidence of post-streptococcal glomerulonephritis (PSGN) and acute rheumatic fever, the prevalence of rheumatic heart disease (RHD), and to estimate morbidity and mortality caused by these diseases globally. METHODS: Systematic literature review and review of World Health Organisation (WHO) vital registration data (VRD). RESULTS: Incidence and prevalence of rheumatic fever and RHD show very significant global variation. The greatest burden was found in sub-Saharan Africa, the lowest in North America. The highest mortality rates from these two diseases were reported in the indigenous populations of Australia (23.8 per 100,000). Among countries with VRD, the highest mortality was found in Mauritius (4.32 per 100,000). A few studies reported mortality from PSGN and these reported low mortality rates (mean 0.028 per 100,000 in developing countries). CONCLUSION: Lack of data from key parts of the world limits our ability to make precise statements of disease burden. Further research and surveillance is required to generate more primary data to inform future estimates.
OBJECTIVES: To establish the incidence of post-streptococcal glomerulonephritis (PSGN) and acute rheumatic fever, the prevalence of rheumatic heart disease (RHD), and to estimate morbidity and mortality caused by these diseases globally. METHODS: Systematic literature review and review of World Health Organisation (WHO) vital registration data (VRD). RESULTS: Incidence and prevalence of rheumatic fever and RHD show very significant global variation. The greatest burden was found in sub-Saharan Africa, the lowest in North America. The highest mortality rates from these two diseases were reported in the indigenous populations of Australia (23.8 per 100,000). Among countries with VRD, the highest mortality was found in Mauritius (4.32 per 100,000). A few studies reported mortality from PSGN and these reported low mortality rates (mean 0.028 per 100,000 in developing countries). CONCLUSION: Lack of data from key parts of the world limits our ability to make precise statements of disease burden. Further research and surveillance is required to generate more primary data to inform future estimates.
Authors: Aniela Wozniak; Natalia Scioscia; Patricia C García; James B Dale; Braulio A Paillavil; Paulette Legarraga; Francisco J Salazar-Echegarai; Susan M Bueno; Alexis M Kalergis Journal: Microbiol Immunol Date: 2018-06-11 Impact factor: 1.955
Authors: James B Dale; Thomas A Penfound; Boubou Tamboura; Samba O Sow; James P Nataro; Milagritos Tapia; Karen L Kotloff Journal: Vaccine Date: 2013-01-31 Impact factor: 3.641
Authors: Brianna Miner; Amanda Purdy; Laura Curtis; Kevin Simonson; Caleb Shumway; Jessa Baker; Jessica Vaughan; Kara Percival; Olivia Sanchez; Shadi Lahham; Linda Joseph; J Christian Fox Journal: World J Emerg Med Date: 2015